FORADIL by Novartis is clinical pharmacology mechanism of action formoterol fumarate is a long-acting selective beta 2 -adrenergic receptor agonist (beta 2 -agonist). Approved for asthma, the prevention of bronchospasm only, such and 3 more indications. First approved in 2001.
Drug data last refreshed 13h ago · AI intelligence enriched 1w ago
FORADIL (formoterol fumarate) is a long-acting selective beta-2 adrenergic receptor agonist (LABA) delivered via inhalation powder for asthma and COPD management. It acts locally in the lung as a bronchodilator by stimulating intracellular adenyl cyclase and increasing cyclic AMP levels, causing bronchial smooth muscle relaxation. The drug is indicated for prevention of bronchospasm in asthma and reversible obstructive airways disease in children 5 years and older, including those with nocturnal symptoms.
Product approaching loss of exclusivity signals declining team investment and potential consolidation of brand-focused commercial roles into generic transition management.
CLINICAL PHARMACOLOGY Mechanism of Action Formoterol fumarate is a long-acting selective beta 2 -adrenergic receptor agonist (beta 2 -agonist). Inhaled formoterol fumarate acts locally in the lung as a bronchodilator. In vitro studies have shown that formoterol has more than 200-fold greater…
Worked on FORADIL at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Study of Safety of Foradil in Patients With Persistent Asthma
Efficacy and Safety Study to Compare Formoterol Fumerate in the Pressair DPI to the Foradil Aerolizer in Patient With Mild to Moderate Asthma
A Study in Asthmatic Children (6 to <12 Yrs) Comparing Single Doses of Formoterol and Foradil® Evaluating Efficacy
Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
FORADIL positions professionals for respiratory market expertise and managed-care negotiations as the product enters LOE transition. Roles focus on defending market share against combination therapies and preparing for generic competition rather than growth initiatives.